Indobufen
- Generic Name
- Indobufen
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H17NO3
- CAS Number
- 63610-08-2
- Unique Ingredient Identifier
- 6T9949G4LZ
- Background
Indobufen has been used in trials studying the supportive care and prevention of Atrial Fibrillation.
- Indication
用于动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成。也可用于血液透析时预防血栓形成。
- Associated Conditions
- Platelet Aggregation
- Associated Therapies
- -
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 2846
- Registration Number
- NCT06451198
Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease
Not Applicable
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Target Recruit Count
- 594
- Registration Number
- NCT04308551
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 5438
- Registration Number
- NCT03871517
- Locations
- 🇨🇳
Beijing Tian Tan Hospital, Capital Medical University, Beijing, Beijing, China
Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2010-11-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01232023
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Pusan, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1372
- Registration Number
- NCT00244426
- Locations
- 🇮🇹
Pfizer Investigational Site, Viterbo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath